Peter Geschek
Peter Geschek
Stop FollowingPeter Geschek
View as an RSS Feed
View Peter Geschek's Articles BY TICKER:
- Bristol Myers Squibb And The New Wave Of Cancer Drugs
- Johnson & Johnson, Medtronic Frontrunners In Race To Develop Artificial Pancreas
- Pfizer's Direct-To-Consumer Campaigns: A Model For The Future?
- Billions In Renal Denervation: Medtronic, St. Jude
-
After AbbVie's Humira: What Next?
- EPO Pills: A Challenge For Amgen And Johnson & Johnson
- Enbrel's Asian Biosimilar Competitors
- Eli Lilly's Big Bet On Diabetes
- Merck's Promising Vaccine Empire
- Sarepta Vs Glaxo In The Race To Treat Muscular Dystrophy
- Is Celgene's Apremilast A Potential Blockbuster Or Not?
- Abbott Laboratories' Golden Goose: The Nutrition Business
- Pfizer's Prevnar 13: The World's Leading Vaccine And Its Competitors
- Johnson & Johnson's New Diabetes Drug And Its Competitors
- Celgene's Star Drug Revlimid And Its Competitors
- Biogen And The Progress In Multiple Sclerosis Treatment
- Gilead And Its Competitors In The Hepatitis C Race
- Express Scripts And The Battle With High Drug Prices
- Amgen's Master Plan To Generate Biosimilar Blockbusters
- Agilent And The Boom In Companion Diagnostics
- Alexion And The Super Drugs At Super High Prices
- Pfizer's Xalkori And The Progress In Lung Cancer Drugs
- Amgen Benefits From Affymax Recall
- Roche, Genentech And The Cancer Drug Billionaires
- Johnson & Johnson's Pioneering Zytiga And Its Competitors
- Pfizer's Long-Term Strategy: A Possible Breakup
- Celgene And The Race To Cure Multiple Myeloma
- How Safe Is Abbvie's Dividend?
- Bright Prospects For The New Abbott
- Intuitive Surgical Fighting Off Short Sellers
- Stryker Increases Dividends, Expands In China
- Bristol-Myers Squibb's Dividend Increase And Promising New Drugs
